KRM 1671

structure in first source

Also Known As:

25-deacetyl-KRM-1648; KRM-1671; Rifamycin VIII, 25-O-deacetyl-1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-(4-(2-methylpropyl)-1-piperazinyl)-1-oxo-

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Rifamycins: 416
      - KRM 1671: 1
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Macrocyclic Lactams: 28
    - Rifamycins: 416
      - KRM 1671: 1

Related Diseases

1.	Tuberculosis (Tuberculoses) 09/01/1998 - "In preclinical in vitro studies, rifalazil was 30-fold more potent than rifampin against M tuberculosis and MAC, and has shown efficacy in animal models of tuberculosis and in disseminated MAC infections that have been predictive of clinical efficacy with other antibiotics [224163].The major metabolites, KRM-1671 and KRM-1690 are as active and slightly less active than the parent compound, respectively [187790]. "
2.	Infections 09/01/1998 - "In preclinical in vitro studies, rifalazil was 30-fold more potent than rifampin against M tuberculosis and MAC, and has shown efficacy in animal models of tuberculosis and in disseminated MAC infections that have been predictive of clinical efficacy with other antibiotics [224163].The major metabolites, KRM-1671 and KRM-1690 are as active and slightly less active than the parent compound, respectively [187790]. "

Related Drugs and Biologics

1.	Rifampin (Rifampicin)
2.	Anti-Bacterial Agents (Antibiotics)
3.	KRM 1648